EP0591275B1 — Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in the treatment of tyrosinaemia and pharmaceutical compositions
Assigned to Syngenta Ltd · Expires 1999-03-31 · 27y expired
What this patent protects
The invention concerns novel pharmaceutical compositions containing as an active ingredient a 2-benzoyl-1,3-cyclohexanedione which is an inhibitor of the enzyme 4-hydroxyphenylpyruvate dioxygenase (HPPD). The compositions are valuable in the treating those disorders and diseases …
USPTO Abstract
The invention concerns novel pharmaceutical compositions containing as an active ingredient a 2-benzoyl-1,3-cyclohexanedione which is an inhibitor of the enzyme 4-hydroxyphenylpyruvate dioxygenase (HPPD). The compositions are valuable in the treating those disorders and diseases in which it is desirable to intervene in the metabolic sequences catalysed by HPPD, such as in treating tyrosinemia type I.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.